Clinical trials
Hepatitis B Virus Infection clinical trials
Below are recruiting hepatitis b virus infection clinical trials, each written for real people, not researchers. We’re tracking 104 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT07454915RecruitingPhase 2
PVX4 vaccine for HPV16-related cervical dysplasia
This trial tests a new vaccine called PVX4 for women with HPV16-related cervical dysplasia. It aims to see if the vaccine can help clear the high-risk HPV infection and the abnormal cells on the cervix.
The Bronx, New YorkAges 18–60 - NCT07555392RecruitingPhase 2/Phase 3
Chikungunya Vaccine Safety and Immune Response Study
This study tests a new vaccine to protect against chikungunya virus, a disease spread by mosquitoes that causes fever and joint pain. The study measures how well your immune system responds to the vaccine and tracks any side effects.
Guwahati, AssamAges 12–65 - NCT03258567RecruitingPhase 2
Nivolumab for EBV-related lymphomas and abnormal immune illnesses
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Bethesda, MarylandAges 12 years+ - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT07706686RecruitingPhase 1
Dengue challenge study in people with prior infection
This study tests how the body responds to a mild, lab-made dengue virus in people who have had dengue before. It looks at how the immune system reacts to a second infection, which may help improve future vaccines and treatments.
Bethesda, MarylandAges 18–50 - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT05583006Recruiting
Switch from entecavir to tenofovir for chronic hepatitis B
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Taichung, TaiwanAges 20 years+ - NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT07306156RecruitingPhase 1/Phase 2
GP350 CAR-T for Epstein-Barr virus related lymphoma
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
Hefei, AnhuiAges 18–70 - NCT07275918RecruitingPhase 1
Study of SA1211 injection for chronic hepatitis B
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
Changchun, JilinAges 18–65 - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT06947356Recruiting
TAF vs TDF to prevent passing hepatitis B to babies
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
Guangzhou, GuangdongAges 20–40 - NCT06966232RecruitingPhase 3
Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT05686759RecruitingPhase 3
Tested IV Hepabig in liver-transplant patients with hepatitis B
This Phase 3 study checks whether an undiluted IV infusion of I.V.-Hepabig inj is safe and works to help prevent hepatitis B from coming back after a liver transplant. It is mainly for adults who had a hepatitis B–related liver transplant and already received Hepabig regularly.
Goyang-si, Gyeonggi-doAges 18–64 - NCT06364930RecruitingPhase 4
SGLT2 inhibitor to prevent liver problems in hepatitis B and diabetes
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
Hong KongAges 18 years+ - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT07725263Recruiting
Low-dose antifungal for kids with low white blood cells
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
Haikou, HainanAges 3–17 - NCT06159504RecruitingEarly Phase 1
Simplifying Hepatitis C Care for People Who Inject Drugs
This study aims to make hepatitis C treatment simpler and more accessible for people who inject drugs. If you join, you'll receive care that fits your lifestyle and helps cure hep C.
YerevanAges 18 years+ - NCT07419347Recruiting
Glecaprevir/Pibrentasvir safety in real-world use
This study watches how safe and well-tolerated the 8-week treatment with glecaprevir/pibrentasvir is for people with hepatitis C who are taking other prescription or illicit drugs. It helps doctors learn more about using this medicine in everyday life.
Vancouver, British ColumbiaAges 18 years+ - NCT05934448RecruitingPhase 2
CAR T plus pembrolizumab for relapsed lymphoma after prior treatment
This Phase 2 trial studies CAR T-cell therapy combined with pembrolizumab for certain hard-to-treat lymphomas that have come back or did not respond. It aims to improve tumor response and outcomes after you’ve already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07763054Recruiting
Low-dose antifungal prevention for patients with low white blood cell counts
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
Hainan, HainanAges 18–75
Hear when a new Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis b virus infection?
- Yes. Clin2 currently lists 104 recruiting hepatitis b virus infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis b virus infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis b virus infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.